ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Nuclear Medicine & Radiopharmaceuticals Market Research Report 2026
Published Date: 2026-02-05
|
Report Code: QYRE-Auto-32U2391
Home | Market Reports | Health| Pharmacy
COVID 19 Impact on Global Nuclear Medicine Radiopharmaceuticals Market Insights Forecast to 2026
BUY CHAPTERS

Global Nuclear Medicine & Radiopharmaceuticals Market Research Report 2026

Code: QYRE-Auto-32U2391
Report
2026-02-05
Pages:122
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
China Isotope & Radiation
Dongcheng
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
Siemens AG
Lantheus
Bracco Imaging
Bayer
Eli Lilly
Aurobindo Pharma
Mundipharma
China Isotope & Radiation

Nuclear Medicine & Radiopharmaceuticals Market Size

The global Nuclear Medicine & Radiopharmaceuticals market was valued at US$ 7116 million in 2025 and is anticipated to reach US$ 11560 million by 2032, at a CAGR of 7.3% from 2026 to 2032.

Nuclear Medicine & Radiopharmaceuticals Market

Nuclear Medicine & Radiopharmaceuticals Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Nuclear Medicine & Radiopharmaceuticals competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis and, increasingly, for the therapy of diseases.
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The radiopharmaceutical market is driven primarily by the growing prevalence of cancer and cardiovascular diseases, which require precise diagnostic tools for early detection and treatment. The increasing adoption of nuclear medicine imaging techniques, such as PET and SPECT scans, has further fueled demand for radiopharmaceuticals. Additionally, technological advancements in radiopharmaceuticals, along with the development of new radioisotopes for more targeted therapies, are expanding the applications of these drugs, making them critical in personalized medicine.
Despite the promising growth, the radiopharmaceutical market faces significant challenges, including the high cost of production and the short half-life of many radioisotopes, which complicates distribution and storage. Regulatory hurdles are another barrier, as radiopharmaceuticals require stringent approval processes due to their radioactive nature. Moreover, limited availability of specialized infrastructure and the shortage of trained professionals in nuclear medicine also hinder widespread adoption, especially in developing regions.
There is widespread awareness of the use of radiation and radioisotopes in medicine, particularly for diagnosis (identification) and therapy (treatment) of various medical conditions. In developed countries (a quarter of the world population) about one person in 50 uses diagnostic nuclear medicine each year, and the frequency of therapy with radioisotopes is about one-tenth of this.
Nuclear medicine uses radiation to provide information about the functioning of a person's specific organs, or to treat disease. In most cases, the information is used by physicians to make a quick diagnosis of the patient's illness. The thyroid, bones, heart, liver, and many other organs can be easily imaged, and disorders in their function revealed. In some cases radiation can be used to treat diseased organs, or tumours.
Over 10,000 hospitals worldwide use radioisotopes in medicine, and about 90% of the procedures are for diagnosis. The most common radioisotope used in diagnosis is technetium-99 (Tc-99m) accounting for about 80% of all nuclear medicine procedures and 85% of diagnostic scans in nuclear medicine worldwide.Over 50 million nuclear medicine procedures are performed each year, and demand for radioisotopes is increasing.
This report delivers a comprehensive overview of the global Nuclear Medicine & Radiopharmaceuticals market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Nuclear Medicine & Radiopharmaceuticals. The Nuclear Medicine & Radiopharmaceuticals market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Nuclear Medicine & Radiopharmaceuticals market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Nuclear Medicine & Radiopharmaceuticals manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Nuclear Medicine & Radiopharmaceuticals Market Report

Report Metric Details
Report Name Nuclear Medicine & Radiopharmaceuticals Market
Accounted market size in 2025 US$ 7116 in million
Forecasted market size in 2032 US$ 11560 million
CAGR 7.3%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Diagnostic Radiopharmaceuticals
  • Therapeutic Radiopharmaceuticals
by Application
  • Oncology
  • Thyroid
  • Cardiology
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Bayer, Eli Lilly, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Dongcheng
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Nuclear Medicine & Radiopharmaceuticals manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Nuclear Medicine & Radiopharmaceuticals sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Nuclear Medicine & Radiopharmaceuticals Market growing?

Ans: The Nuclear Medicine & Radiopharmaceuticals Market witnessing a CAGR of 7.3% during the forecast period 2026-2032.

What is the Nuclear Medicine & Radiopharmaceuticals Market size in 2032?

Ans: The Nuclear Medicine & Radiopharmaceuticals Market size in 2032 will be US$ 11560 million.

Who are the main players in the Nuclear Medicine & Radiopharmaceuticals Market report?

Ans: The main players in the Nuclear Medicine & Radiopharmaceuticals Market are Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Bayer, Eli Lilly, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Dongcheng

What are the Application segmentation covered in the Nuclear Medicine & Radiopharmaceuticals Market report?

Ans: The Applications covered in the Nuclear Medicine & Radiopharmaceuticals Market report are Oncology, Thyroid, Cardiology, Others

What are the Type segmentation covered in the Nuclear Medicine & Radiopharmaceuticals Market report?

Ans: The Types covered in the Nuclear Medicine & Radiopharmaceuticals Market report are Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals

1 Nuclear Medicine & Radiopharmaceuticals Market Overview
1.1 Product Definition
1.2 Nuclear Medicine & Radiopharmaceuticals by Type
1.2.1 Global Nuclear Medicine & Radiopharmaceuticals Market Value by Type: 2025 vs 2032
1.2.2 Diagnostic Radiopharmaceuticals
1.2.3 Therapeutic Radiopharmaceuticals
1.3 Nuclear Medicine & Radiopharmaceuticals by Application
1.3.1 Global Nuclear Medicine & Radiopharmaceuticals Market Value by Application: 2025 vs 2032
1.3.2 Oncology
1.3.3 Thyroid
1.3.4 Cardiology
1.3.5 Others
1.4 Global Nuclear Medicine & Radiopharmaceuticals Market Size Estimates and Forecasts
1.4.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue 2021–2032
1.4.2 Global Nuclear Medicine & Radiopharmaceuticals Sales 2021–2032
1.4.3 Global Nuclear Medicine & Radiopharmaceuticals Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Nuclear Medicine & Radiopharmaceuticals Market Competition by Manufacturers
2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Manufacturers (2021–2026)
2.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Nuclear Medicine & Radiopharmaceuticals Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Nuclear Medicine & Radiopharmaceuticals, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Product Types and Applications
2.7 Global Key Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Date of Entry into the Industry
2.8 Global Nuclear Medicine & Radiopharmaceuticals Market Competitive Situation and Trends
2.8.1 Global Nuclear Medicine & Radiopharmaceuticals Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Nuclear Medicine & Radiopharmaceuticals Players Market Share by Revenue
2.8.3 Global Nuclear Medicine & Radiopharmaceuticals Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Nuclear Medicine & Radiopharmaceuticals Market Scenario by Region
3.1 Global Nuclear Medicine & Radiopharmaceuticals Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region: 2021–2032
3.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region: 2021–2026
3.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region: 2027–2032
3.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region: 2021–2032
3.3.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region: 2021–2026
3.3.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region: 2027–2032
3.4 North America Nuclear Medicine & Radiopharmaceuticals Market Facts & Figures by Country
3.4.1 North America Nuclear Medicine & Radiopharmaceuticals Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Nuclear Medicine & Radiopharmaceuticals Sales by Country (2021–2032)
3.4.3 North America Nuclear Medicine & Radiopharmaceuticals Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Nuclear Medicine & Radiopharmaceuticals Market Facts & Figures by Country
3.5.1 Europe Nuclear Medicine & Radiopharmaceuticals Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Nuclear Medicine & Radiopharmaceuticals Sales by Country (2021–2032)
3.5.3 Europe Nuclear Medicine & Radiopharmaceuticals Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nuclear Medicine & Radiopharmaceuticals Market Facts & Figures by Region
3.6.1 Asia Pacific Nuclear Medicine & Radiopharmaceuticals Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Nuclear Medicine & Radiopharmaceuticals Sales by Region (2021–2032)
3.6.3 Asia Pacific Nuclear Medicine & Radiopharmaceuticals Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Nuclear Medicine & Radiopharmaceuticals Market Facts & Figures by Country
3.7.1 Latin America Nuclear Medicine & Radiopharmaceuticals Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Nuclear Medicine & Radiopharmaceuticals Sales by Country (2021–2032)
3.7.3 Latin America Nuclear Medicine & Radiopharmaceuticals Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Market Facts & Figures by Country
3.8.1 Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Sales by Country (2021–2032)
3.8.3 Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (2021–2032)
4.1.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (2021–2026)
4.1.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (2027–2032)
4.1.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Type (2021–2032)
4.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type (2021–2032)
4.2.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type (2021–2026)
4.2.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type (2027–2032)
4.2.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Type (2021–2032)
4.3 Global Nuclear Medicine & Radiopharmaceuticals Price by Type (2021–2032)
5 Segment by Application
5.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (2021–2032)
5.1.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (2021–2026)
5.1.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (2027–2032)
5.1.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Application (2021–2032)
5.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Application (2021–2032)
5.2.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Application (2021–2026)
5.2.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Application (2027–2032)
5.2.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Application (2021–2032)
5.3 Global Nuclear Medicine & Radiopharmaceuticals Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Cardinal Health
6.1.1 Cardinal Health Company Information
6.1.2 Cardinal Health Description and Business Overview
6.1.3 Cardinal Health Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Cardinal Health Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.1.5 Cardinal Health Recent Developments/Updates
6.2 GE Healthcare
6.2.1 GE Healthcare Company Information
6.2.2 GE Healthcare Description and Business Overview
6.2.3 GE Healthcare Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 GE Healthcare Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.2.5 GE Healthcare Recent Developments/Updates
6.3 Jubilant Pharma
6.3.1 Jubilant Pharma Company Information
6.3.2 Jubilant Pharma Description and Business Overview
6.3.3 Jubilant Pharma Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Jubilant Pharma Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.3.5 Jubilant Pharma Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Novartis Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Curium Pharma
6.5.1 Curium Pharma Company Information
6.5.2 Curium Pharma Description and Business Overview
6.5.3 Curium Pharma Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Curium Pharma Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.5.5 Curium Pharma Recent Developments/Updates
6.6 SIEMENS
6.6.1 SIEMENS Company Information
6.6.2 SIEMENS Description and Business Overview
6.6.3 SIEMENS Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 SIEMENS Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.6.5 SIEMENS Recent Developments/Updates
6.7 Lantheus
6.7.1 Lantheus Company Information
6.7.2 Lantheus Description and Business Overview
6.7.3 Lantheus Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Lantheus Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.7.5 Lantheus Recent Developments/Updates
6.8 Bracco Imaging
6.8.1 Bracco Imaging Company Information
6.8.2 Bracco Imaging Description and Business Overview
6.8.3 Bracco Imaging Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Bracco Imaging Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.8.5 Bracco Imaging Recent Developments/Updates
6.9 Bayer
6.9.1 Bayer Company Information
6.9.2 Bayer Description and Business Overview
6.9.3 Bayer Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Bayer Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.9.5 Bayer Recent Developments/Updates
6.10 Eli Lilly
6.10.1 Eli Lilly Company Information
6.10.2 Eli Lilly Description and Business Overview
6.10.3 Eli Lilly Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Eli Lilly Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.10.5 Eli Lilly Recent Developments/Updates
6.11 Aurobindo Pharma
6.11.1 Aurobindo Pharma Company Information
6.11.2 Aurobindo Pharma Description and Business Overview
6.11.3 Aurobindo Pharma Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Aurobindo Pharma Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.11.5 Aurobindo Pharma Recent Developments/Updates
6.12 Mundipharma
6.12.1 Mundipharma Company Information
6.12.2 Mundipharma Description and Business Overview
6.12.3 Mundipharma Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Mundipharma Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.12.5 Mundipharma Recent Developments/Updates
6.13 China Isotope & Radiation
6.13.1 China Isotope & Radiation Company Information
6.13.2 China Isotope & Radiation Description and Business Overview
6.13.3 China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.13.5 China Isotope & Radiation Recent Developments/Updates
6.14 Dongcheng
6.14.1 Dongcheng Company Information
6.14.2 Dongcheng Description and Business Overview
6.14.3 Dongcheng Nuclear Medicine & Radiopharmaceuticals Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Dongcheng Nuclear Medicine & Radiopharmaceuticals Product Portfolio
6.14.5 Dongcheng Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nuclear Medicine & Radiopharmaceuticals Industry Chain Analysis
7.2 Nuclear Medicine & Radiopharmaceuticals Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nuclear Medicine & Radiopharmaceuticals Production Mode & Process Analysis
7.4 Nuclear Medicine & Radiopharmaceuticals Sales and Marketing
7.4.1 Nuclear Medicine & Radiopharmaceuticals Sales Channels
7.4.2 Nuclear Medicine & Radiopharmaceuticals Distributors
7.5 Nuclear Medicine & Radiopharmaceuticals Customer Analysis
8 Nuclear Medicine & Radiopharmaceuticals Market Dynamics
8.1 Nuclear Medicine & Radiopharmaceuticals Industry Trends
8.2 Nuclear Medicine & Radiopharmaceuticals Market Drivers
8.3 Nuclear Medicine & Radiopharmaceuticals Market Challenges
8.4 Nuclear Medicine & Radiopharmaceuticals Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
China Isotope & Radiation
Dongcheng
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
Siemens AG
Lantheus
Bracco Imaging
Bayer
Eli Lilly
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
List of Tables
 Table 1. Global Nuclear Medicine & Radiopharmaceuticals Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Nuclear Medicine & Radiopharmaceuticals Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Nuclear Medicine & Radiopharmaceuticals Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Nuclear Medicine & Radiopharmaceuticals Sales (K Dose) of Key Manufacturers (2021–2026)
 Table 5. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Nuclear Medicine & Radiopharmaceuticals Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Nuclear Medicine & Radiopharmaceuticals Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Nuclear Medicine & Radiopharmaceuticals Average Price (US$/Dose) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Nuclear Medicine & Radiopharmaceuticals, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Product Types and Applications
 Table 12. Global Key Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Nuclear Medicine & Radiopharmaceuticals Companies by Tier (Tier 1, Tier 2, Tier 3), based on Nuclear Medicine & Radiopharmaceuticals Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Nuclear Medicine & Radiopharmaceuticals Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Nuclear Medicine & Radiopharmaceuticals Sales by Region (K Dose), 2021–2026
 Table 18. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Region (2021–2026)
 Table 19. Global Nuclear Medicine & Radiopharmaceuticals Sales by Region (K Dose), 2027–2032
 Table 20. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Region (2027–2032)
 Table 21. Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Region (2021–2026)
 Table 23. Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Region (2027–2032)
 Table 25. North America Nuclear Medicine & Radiopharmaceuticals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Nuclear Medicine & Radiopharmaceuticals Sales by Country (K Dose), 2021–2026
 Table 27. North America Nuclear Medicine & Radiopharmaceuticals Sales by Country (K Dose), 2027–2032
 Table 28. North America Nuclear Medicine & Radiopharmaceuticals Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Nuclear Medicine & Radiopharmaceuticals Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Nuclear Medicine & Radiopharmaceuticals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Nuclear Medicine & Radiopharmaceuticals Sales by Country (K Dose), 2021–2026
 Table 32. Europe Nuclear Medicine & Radiopharmaceuticals Sales by Country (K Dose), 2027–2032
 Table 33. Europe Nuclear Medicine & Radiopharmaceuticals Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Nuclear Medicine & Radiopharmaceuticals Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Nuclear Medicine & Radiopharmaceuticals Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Nuclear Medicine & Radiopharmaceuticals Sales by Region (K Dose), 2021–2026
 Table 37. Asia Pacific Nuclear Medicine & Radiopharmaceuticals Sales by Region (K Dose), 2027–2032
 Table 38. Asia Pacific Nuclear Medicine & Radiopharmaceuticals Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Nuclear Medicine & Radiopharmaceuticals Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Nuclear Medicine & Radiopharmaceuticals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Nuclear Medicine & Radiopharmaceuticals Sales by Country (K Dose), 2021–2026
 Table 42. Latin America Nuclear Medicine & Radiopharmaceuticals Sales by Country (K Dose), 2027–2032
 Table 43. Latin America Nuclear Medicine & Radiopharmaceuticals Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Nuclear Medicine & Radiopharmaceuticals Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Sales by Country (K Dose), 2021–2026
 Table 47. Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Sales by Country (K Dose), 2027–2032
 Table 48. Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Nuclear Medicine & Radiopharmaceuticals Sales (K Dose) by Type (2021–2026)
 Table 51. Global Nuclear Medicine & Radiopharmaceuticals Sales (K Dose) by Type (2027–2032)
 Table 52. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Type (2021–2026)
 Table 53. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Type (2027–2032)
 Table 54. Global Nuclear Medicine & Radiopharmaceuticals Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Nuclear Medicine & Radiopharmaceuticals Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Type (2021–2026)
 Table 57. Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Type (2027–2032)
 Table 58. Global Nuclear Medicine & Radiopharmaceuticals Price (US$/Dose) by Type (2021–2026)
 Table 59. Global Nuclear Medicine & Radiopharmaceuticals Price (US$/Dose) by Type (2027–2032)
 Table 60. Global Nuclear Medicine & Radiopharmaceuticals Sales (K Dose) by Application (2021–2026)
 Table 61. Global Nuclear Medicine & Radiopharmaceuticals Sales (K Dose) by Application (2027–2032)
 Table 62. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Application (2021–2026)
 Table 63. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Application (2027–2032)
 Table 64. Global Nuclear Medicine & Radiopharmaceuticals Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Nuclear Medicine & Radiopharmaceuticals Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Application (2021–2026)
 Table 67. Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Application (2027–2032)
 Table 68. Global Nuclear Medicine & Radiopharmaceuticals Price (US$/Dose) by Application (2021–2026)
 Table 69. Global Nuclear Medicine & Radiopharmaceuticals Price (US$/Dose) by Application (2027–2032)
 Table 70. Cardinal Health Company Information
 Table 71. Cardinal Health Description and Business Overview
 Table 72. Cardinal Health Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 73. Cardinal Health Nuclear Medicine & Radiopharmaceuticals Product
 Table 74. Cardinal Health Recent Developments/Updates
 Table 75. GE Healthcare Company Information
 Table 76. GE Healthcare Description and Business Overview
 Table 77. GE Healthcare Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 78. GE Healthcare Nuclear Medicine & Radiopharmaceuticals Product
 Table 79. GE Healthcare Recent Developments/Updates
 Table 80. Jubilant Pharma Company Information
 Table 81. Jubilant Pharma Description and Business Overview
 Table 82. Jubilant Pharma Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 83. Jubilant Pharma Nuclear Medicine & Radiopharmaceuticals Product
 Table 84. Jubilant Pharma Recent Developments/Updates
 Table 85. Novartis Company Information
 Table 86. Novartis Description and Business Overview
 Table 87. Novartis Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 88. Novartis Nuclear Medicine & Radiopharmaceuticals Product
 Table 89. Novartis Recent Developments/Updates
 Table 90. Curium Pharma Company Information
 Table 91. Curium Pharma Description and Business Overview
 Table 92. Curium Pharma Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 93. Curium Pharma Nuclear Medicine & Radiopharmaceuticals Product
 Table 94. Curium Pharma Recent Developments/Updates
 Table 95. SIEMENS Company Information
 Table 96. SIEMENS Description and Business Overview
 Table 97. SIEMENS Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 98. SIEMENS Nuclear Medicine & Radiopharmaceuticals Product
 Table 99. SIEMENS Recent Developments/Updates
 Table 100. Lantheus Company Information
 Table 101. Lantheus Description and Business Overview
 Table 102. Lantheus Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 103. Lantheus Nuclear Medicine & Radiopharmaceuticals Product
 Table 104. Lantheus Recent Developments/Updates
 Table 105. Bracco Imaging Company Information
 Table 106. Bracco Imaging Description and Business Overview
 Table 107. Bracco Imaging Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 108. Bracco Imaging Nuclear Medicine & Radiopharmaceuticals Product
 Table 109. Bracco Imaging Recent Developments/Updates
 Table 110. Bayer Company Information
 Table 111. Bayer Description and Business Overview
 Table 112. Bayer Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 113. Bayer Nuclear Medicine & Radiopharmaceuticals Product
 Table 114. Bayer Recent Developments/Updates
 Table 115. Eli Lilly Company Information
 Table 116. Eli Lilly Description and Business Overview
 Table 117. Eli Lilly Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 118. Eli Lilly Nuclear Medicine & Radiopharmaceuticals Product
 Table 119. Eli Lilly Recent Developments/Updates
 Table 120. Aurobindo Pharma Company Information
 Table 121. Aurobindo Pharma Description and Business Overview
 Table 122. Aurobindo Pharma Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 123. Aurobindo Pharma Nuclear Medicine & Radiopharmaceuticals Product
 Table 124. Aurobindo Pharma Recent Developments/Updates
 Table 125. Mundipharma Company Information
 Table 126. Mundipharma Description and Business Overview
 Table 127. Mundipharma Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 128. Mundipharma Nuclear Medicine & Radiopharmaceuticals Product
 Table 129. Mundipharma Recent Developments/Updates
 Table 130. China Isotope & Radiation Company Information
 Table 131. China Isotope & Radiation Description and Business Overview
 Table 132. China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 133. China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Product
 Table 134. China Isotope & Radiation Recent Developments/Updates
 Table 135. Dongcheng Company Information
 Table 136. Dongcheng Description and Business Overview
 Table 137. Dongcheng Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 138. Dongcheng Nuclear Medicine & Radiopharmaceuticals Product
 Table 139. Dongcheng Recent Developments/Updates
 Table 140. Key Raw Materials Lists
 Table 141. Raw Materials Key Suppliers Lists
 Table 142. Nuclear Medicine & Radiopharmaceuticals Distributors List
 Table 143. Nuclear Medicine & Radiopharmaceuticals Customers List
 Table 144. Nuclear Medicine & Radiopharmaceuticals Market Trends
 Table 145. Nuclear Medicine & Radiopharmaceuticals Market Drivers
 Table 146. Nuclear Medicine & Radiopharmaceuticals Market Challenges
 Table 147. Nuclear Medicine & Radiopharmaceuticals Market Restraints
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources
 Table 151. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Nuclear Medicine & Radiopharmaceuticals
 Figure 2. Global Nuclear Medicine & Radiopharmaceuticals Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Nuclear Medicine & Radiopharmaceuticals Market Share by Type: 2025 & 2032
 Figure 4. Diagnostic Radiopharmaceuticals Product Picture
 Figure 5. Therapeutic Radiopharmaceuticals Product Picture
 Figure 6. Global Nuclear Medicine & Radiopharmaceuticals Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Nuclear Medicine & Radiopharmaceuticals Market Share by Application: 2025 & 2032
 Figure 8. Oncology
 Figure 9. Thyroid
 Figure 10. Cardiology
 Figure 11. Others
 Figure 12. Global Nuclear Medicine & Radiopharmaceuticals Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 13. Global Nuclear Medicine & Radiopharmaceuticals Market Size (US$ Million), 2021–2032
 Figure 14. Global Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), 2021–2032
 Figure 15. Global Nuclear Medicine & Radiopharmaceuticals Average Price (US$/Dose), 2021–2032
 Figure 16. Nuclear Medicine & Radiopharmaceuticals Report Years Considered
 Figure 17. Nuclear Medicine & Radiopharmaceuticals Sales Share by Manufacturers in 2025
 Figure 18. Global Nuclear Medicine & Radiopharmaceuticals Revenue Share by Manufacturers in 2025
 Figure 19. Top 5 and Top 10 Global Nuclear Medicine & Radiopharmaceuticals Players: Market Share by Revenue in Nuclear Medicine & Radiopharmaceuticals in 2025
 Figure 20. Nuclear Medicine & Radiopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 21. Global Nuclear Medicine & Radiopharmaceuticals Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 22. North America Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Country (2021–2032)
 Figure 23. North America Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Country (2021–2032)
 Figure 24. U.S. Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Canada Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 26. Europe Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Country (2021–2032)
 Figure 27. Europe Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Country (2021–2032)
 Figure 28. Germany Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. France Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. U.K. Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Italy Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Russia Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Asia Pacific Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Region (2021–2032)
 Figure 34. Asia Pacific Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Region (2021–2032)
 Figure 35. China Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. Japan Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. South Korea Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. India Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Australia Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. China Taiwan Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Indonesia Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Thailand Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Malaysia Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Latin America Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Country (2021–2032)
 Figure 45. Latin America Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Country (2021–2032)
 Figure 46. Mexico Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Brazil Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Argentina Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Country (2021–2032)
 Figure 50. Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Country (2021–2032)
 Figure 51. Turkey Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Saudi Arabia Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. UAE Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. Global Sales Market Share of Nuclear Medicine & Radiopharmaceuticals by Type (2021–2032)
 Figure 55. Global Revenue Market Share of Nuclear Medicine & Radiopharmaceuticals by Type (2021–2032)
 Figure 56. Global Nuclear Medicine & Radiopharmaceuticals Price (US$/Dose) by Type (2021–2032)
 Figure 57. Global Sales Market Share of Nuclear Medicine & Radiopharmaceuticals by Application (2021–2032)
 Figure 58. Global Revenue Market Share of Nuclear Medicine & Radiopharmaceuticals by Application (2021–2032)
 Figure 59. Global Nuclear Medicine & Radiopharmaceuticals Price (US$/Dose) by Application (2021–2032)
 Figure 60. Nuclear Medicine & Radiopharmaceuticals Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Radiopharmaceutical Market Research Report 2025
Global SPECT and PET Radiopharmaceuticals Market Research Report 2024
Global Nuclear Medicine Market Research Report 2025
Global Radiopharmaceuticals in Nuclear Medicine Market Research Report 2025
Global Radiopharmaceutical Therapy Market Research Report 2025
Global Diagnostic Radiopharmaceuticals Market Research Report 2024
Global Diagnostic Nuclear Medicines Market Insights Forecast to 2030
Global Radiopharmaceuticals for Diagnosis Market Research Report 2024
Global Diagnostic Radioisotopes Market Insights Forecast to 2030
Global SPECT Radiopharmaceuticals Market Research Report 2025
Global Targeted Radiopharmaceuticals Market Research Report 2024
Radiopharmaceutical Theranostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Radioactive Therapeutic Drugs Market Research Report 2024
Global Radiopharmaceutical Injector Market Research Report 2025
Global PET Radioisotope Radiopharmaceuticals in PET Imaging Market Research Report 2024
Global Radioisotopes in Medicine Market Research Report 2025
Global Therapeutic Radiopharmaceuticals Market Insights Forecast to 2030
Global Medical Radioisotopes Market Research Report 2025
Nuclear Medicine Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Nuclear Medicine Radioisotopes Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions